Free Trial
NASDAQ:UNCY

Unicycive Therapeutics 11/14/2023 Earnings Report

Unicycive Therapeutics logo
$0.61 -0.02 (-3.89%)
As of 10:04 AM Eastern

Unicycive Therapeutics EPS Results

Actual EPS
-$0.13
Consensus EPS
-$0.13
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Unicycive Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Unicycive Therapeutics Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Unicycive Therapeutics' next earnings date is estimated for Monday, May 12, 2025, based on past reporting schedules.

Conference Call Resources

Unicycive Therapeutics Earnings Headlines

Feds Just Admitted It—They Can Take Your Cash
The Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money isn't legally yours. Now, think your savings are safe? Think again.
Unicycive Therapeutics initiated with a Buy at Guggenheim
Unicycive presents new patient-level data from Phase 2 study of OLC
See More Unicycive Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Unicycive Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Unicycive Therapeutics and other key companies, straight to your email.

About Unicycive Therapeutics

Unicycive Therapeutics (NASDAQ:UNCY), a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

View Unicycive Therapeutics Profile

More Earnings Resources from MarketBeat